Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization

Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang, Richa Bashyal

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Objective: To address gaps in the literature on healthcare resource utilization (HRU) and costs among patients with schizophrenia and prior hospitalization who transition from oral risperidone or paliperidone (oral ris/pali) to once-monthly paliperidone palmitate (PP1M) in a real-world setting by comparing treatment patterns, HRU, and costs 12-months pre- and post-transition to PP1M among Veterans Health Administration (VHA) patients affected by schizophrenia who have had ≥1 hospitalization. Methods: VHA patients with schizophrenia (aged ≥18 years) who initiated oral ris/pali, had ≥1 all-cause inpatient stay, and transitioned to PP1M from January 2015–March 2017 were included from the VHA database. The first transition date to PP1M was identified as the index date. Patients were required to have continuous health plan eligibility for 12 months pre- and post-PP1M. Outcomes were compared using the Wilcoxon signed-rank and McNemar’s test, as appropriate. Results: The study included 319 patients (mean [SD] age = 51.6 [4.2] years) during 12 months of baseline and follow-up. During pre-PP1M transition, 7.2% of the patients were adherent (proportion of days covered [PDC] ≥ 80%) to oral ris/pali. Post-PP1M transition, 27.6% of the patients were adherent to PP1M. Comparison of HRU outcomes from the pre- to post-PP1M transition revealed significantly lower all-cause inpatient stays (3.5 vs 1.4, p <.0001) and shorter inpatient length of stay (43.4 vs 18.3 days, p <.0001). Similar trends were seen for mental health and schizophrenia-related HRU. Cost outcome comparison indicated significantly lower all-cause inpatient costs ($64,702 vs $24,147, p <.0001), total medical costs ($87,917 vs $56,947, p <.0001), and total costs ($91,181 vs $69,106, p <.0001). A similar trend was observed for mental health and schizophrenia-related costs. Conclusions: Transitioning from oral ris/pali to PP1M may significantly improve HRU and provide potential cost savings in VHA patients with schizophrenia and ≥1 prior hospitalization.

Original languageEnglish (US)
Pages (from-to)2159-2168
Number of pages10
JournalCurrent Medical Research and Opinion
Volume35
Issue number12
DOIs
StatePublished - Dec 2 2019
Externally publishedYes

Keywords

  • Schizophrenia
  • antipsychotic agents
  • healthcare costs
  • medication adherence
  • paliperidone palmitate

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization'. Together they form a unique fingerprint.

Cite this